Wound Management News

Immunoglobulin A epidermolysis bullosa acquisita may be more common than previous data would indicate and is likely a separate entity from linear IgA bullous dermatosis, according to an investigation.

Diabetes and hyperlipidemia are both associated with granuloma annulare and may be risk factors for its development, according to a study.

Digital ulcers in patients with systemic sclerosis often need early assessment and systemic treatments, according to a review published in JAMA Dermatology.

StrataGraft, a bioengineered bilayer construct designed to mimic human skin, has been approved by the FDA for the treatment of thermal burns in which intact dermal elements remain and surgical intervention is indicated.

Granuloma annulare is more common among women and middle-aged individuals, but it remains a rare disease in the United States.

The FDA has expanded its approval of the Recell system in combination with meshed autografting to include treatment of acute full-thickness thermal burn wounds in pediatric patients, Avita Medical announced in a press release.

Timolol may be an effective and inexpensive treatment for wound healing, according to a poster presented at AAD VMX 2021.

Traumatic skin wounds may be a risk factor for infective endocarditis in the weeks after wound development, according to findings published in Heart.

Researchers will analyze the safety and efficacy of gene-corrected fibroblasts for the treatment of recessive dystrophic epidermolysis bullosa, according to a presentation at the South Beach Symposium Medical Dermatology Summit.

The first patient has been dosed in a phase 3 clinical trial of debcoemagene autoficel for the treatment of recessive dystrophic epidermolysis bullosa, Castle Creek Biosciences announced in a press release.